Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – ACCEPTANCE OF THE NEW DRUG APPLICATIONS FOR TORIPALIMAB INJECTION (SUBCUTANEOUS INJECTION)

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 9 March 2026.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration recently. The new drug applications ("**NDAs**") for the Company's product, toripalimab injection (subcutaneous injection) (code: JS001sc), for 12 indications in the treatment of tumors have been accepted.

ABOUT JS001sc

Drug name: Toripalimab Injection (subcutaneous injection)
Application matter: Registration of Domestic Production of Pharmaceutical Product
Acceptance No.:CXSS2600035, CXSS2600036, CXSS2600037, CXSS2600038, CXSS2600040, CXSS2600041, CXSS2600042, CXSS2600043, CXSS2600044, CXSS2600045, CXSS2600046, CXSS2600047
Applicant: Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司)
Specification: 180 mg (1 ml) in a single dose (pre-filled syringe)
Review conclusion: It is decided to be accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China* (《中華人民共和國行政許可法》).

JS001sc is a subcutaneous injection formulation developed by the Company based on the marketed product toripalimab injection (code: JS001). It is the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to enter the marketing application stage, and is expected to bring convenient administration to patients. The 12 indications in the NDAs of JS001sc covers all currently approved indications of toripalimab injection in Chinese Mainland.

According to data released by GLOBOCAN 2022, in 2022, there were 4.8247 million new cancer cases, and 2.5742 million cancer-related deaths in China. Immunotherapy (I-O), represented by anti-PD-1 monoclonal antibodies, has become a cornerstone treatment for various malignant tumors, including lung cancer, breast cancer, liver cancer, esophageal cancer, and nasopharyngeal carcinoma, and covers nearly the entire treatment for cancer patients, encompassing adjuvant/neoadjuvant treatment for early-stage tumors, consolidation treatment after radical chemoradiation for locally advanced tumors, and first-line to last-line treatments for advanced tumors. Currently, most immunotherapy drugs in China are administered intravenously, and this not only requires lengthy infusion times but also imposes significant inconvenience on patients. There is an urgent clinical need to enhance the convenience of immunotherapy.

The NDAs are mainly based on the JS001sc-002-III-NSCLC Study (NCT06505837), a multi-center, open-label, randomized phase III clinical study led by principal investigator Professor Wu Lin from Hunan Cancer Hospital* (湖南省腫瘤醫院). The study aimed to compare the exposure, efficacy and safety of JS001sc versus JS001 in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small-cell lung cancer ("**NSCLC**"). The results showed that JS001sc's exposure was non-inferior to that of JS001 with comparable efficacy and safety profiles. JS001sc-002-III-NSCLC was the first phase III clinical study of domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation. Further details will be presented at a recent international academic conference.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above project and fulfill its information disclosure obligations in a timely manner for subsequent progress of the project in strict compliance with relevant regulations.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 9 March 2026

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purpose only*